Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease
1. Olpasiran significantly and substantially reduced lipoprotein(a) concentration in patients with atherosclerotic cardiovascular disease compared to placebo. 2. Olpasiran reduced ...